A Phase 3 interventional study of Rituximab in Lymphoma, Non Hodgkin, sponsored by Hoffmann-La Roche. Completed at 39 sites in Spain. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-12-26.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 178 studies testing rituximab in Lymphoma, Non-Hodgkin — 5 open to participants now, 11 under way, 2 of them phase 3. Rituximab · Lymphoma, Non-Hodgkin.
Among the 178 studies testing rituximab in Lymphoma, Non-Hodgkin, this one is the 30th largest by enrollment of the 171 interventional ones that give a count, is one of 8 that started in 2013, is one of 29 in phase 3, and was the 139th registered.
2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.
Browse Lymphoma, Non-Hodgkin studies →5 of the 178 studies testing rituximab in Lymphoma, Non-Hodgkin are open now, in 2 countries. Recruiting first, the newest first:
Paolo Caimi, MD · Sites in United States
Ages 18+
Reid Merryman, MD · Sites in United States
Ages 18+
University of Cologne · Sites in Germany
Ages 18–99
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
M.D. Anderson Cancer Center · Sites in United States
Ages 15–80
By country, each count listing its studies:
Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
178 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 43 · Phase 2 112 · Phase 3 30 · Phase 4 5
First in 1995; this study’s year is marked. 8 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 140 is above the median of 40 across 1,883 interventional studies indexed under Lymphoma, Non-Hodgkin.
Median enrollment 38 across the 171 interventional studies. Of the 152 that completed or were terminated, 80 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 178 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
54 studies in Lymphoma, Non-Hodgkin by Hoffmann-La Roche: 1 open now, 6 under way, 1 of them phase 3. Of 47 finished, 22 (47%) have results posted.
Among the 54 studies in Lymphoma, Non-Hodgkin by Hoffmann-La Roche, this one is the 19th largest by enrollment of the 49 interventional ones that give a count, is one of 3 that started in 2013, is one of 11 in phase 3, and was the 30th registered.
Hoffmann-La Roche’s Lymphoma, Non-Hodgkin studies by the year they started, since 1997.
4 of the studies testing rituximab in Lymphoma, Non-Hodgkin that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05578976Phase 3GenmabA Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) | 2027-06 |
| NCT05583071University of CologneMethotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL | 2027-02 |
| NCT01829958Memorial Sloan Kettering Cancer CenterComprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy | 2027-04 |
| NCT02727803M.D. Anderson Cancer CenterPersonalized NK Cell Therapy in CBT | 2027-05-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 178 studies testing rituximab in Lymphoma, Non-Hodgkin, from their registry updates:
Among Hoffmann-La Roche’s 54 in Lymphoma, Non-Hodgkin:
This tab as a report to print or save as PDF → With an account.
This open-label, single-arm, phase IIIb study will evaluate the safety of switching from intravenous (IV) to subcutaneous (SC) administration of rituximab during first-line treatment for participants with CD20+ non-Hodgkin's follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL) who have already received at least one full dose of rituximab IV. Participants with FL will be given 1400 mg rituximab SC during induction therapy (once monthly for 4-7 cycles) and maintenance therapy (once every 2 months for 6-12 cycles). 1400 mg SC of rituximab will be given to participants with DLBCL once monthly for 4-7 cycles. Treatment duration is expected to last up to 7 months for participants with DLBCL and up to 32 months for participants with FL.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Induction only:
FL treatment-related criteria
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with CD20+ non-Hodgkin's follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL), who had already received at least one full dose of intravenous (IV) rituximab will be treated with subcutaneous (SC) rituximab. Participants with FL will be administered 1400 mg rituximab during induction therapy (once monthly for 4-7 cycles) and maintenance therapy (once every 2 months for 6-12 cycles). Participants with DLBCL will be administered 1400 mg SC of rituximab once monthly for 4-7 cycles. Treatment duration is expected to last up to 7 months for participants with DLBCL and up to 32 months for participants with FL.
Drug: Rituximab
1400 mg will be injected subcutaneously (SC).
Also known as: MabThera, Rituxan
Percentage of Participants With Administration-Associated Reactions (AARs)
AARs were defined as all adverse events (AEs) occurring within 24 hours of rituximab SC administration and which were considered related to study drug. AARs included infusion/injection-related reactions (IIRRs), injection-site reactions, administration site conditions and all symptoms thereof. Grading was completed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.0.
Time frame: From start of treatment to end of treatment (up to 32 months)
Percentage of Participants With At Least One Grade >/= 3 Adverse Events (AEs)
An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsen during a study are also considered as adverse events. Grading was completed according to the CTCAE, version 4.0.
Time frame: From start of recruitment (10 months period) up to end of treatment at 32 months (total period up to 42 months)
Percentage of Participants With At Least One Grade >/= 3 Infusion/ Injection Related Reactions (IIRRs)
Grading of IIRRs was completed according to the CTCAE, version 4.0.
Time frame: From start of treatment to end of treatment (up to 32 months)
Percentage of Participants With At Least One Serious Adverse Event (SAE)
SAE was defined as any experience that suggested a significant hazard, contraindication, side effect, or precaution, and fulfilled any of the following criteria: fatal (resulted in death), life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/ birth defect, was medically significant or required intervention to prevent any of the other outcomes listed here.
Time frame: From start of recruitment (10 months period) up to end of treatment at 32 months (total period up to 42 months)
Event-Free Survival (EFS)
EFS was defined as the time from first dose of rituximab IV to first occurrence of progressive disease (PD) or relapse, according to the International Working Group (IWG) response criteria or initiation of a non-protocol-specified anti-lymphoma therapy or death, whichever occurs first. PD: \>/= 50% increase lymph nodes and nodal mass size, any new lesion, enlarged liver/spleen, reappearance bone marrow abnormalities.
Time frame: From time of first dose of rituximab IV before study enrollment up to end of study (up to approximately 62 months)
Progression-Free Survival (PFS)
PFS was defined as the time from first dose of rituximab IV to the first occurrence of progressive disease (PD) or relapse, according to the International Working Group (IWG) response criteria or death from any cause. PD: \>/= 50% increase lymph nodes and nodal mass size, any new lesion, enlarged liver/spleen, reappearance bone marrow abnormalities.
Time frame: From time of first dose of rituximab IV before study enrollment up to end of study (up to approximately 62 months)
Overall Survival (OS)
OS was defined as the time from first dose of rituximab IV to death from any cause.
Time frame: From time of first dose of rituximab IV before study enrollment up to end of study (up to approximately 62 months)
Disease-Free Survival (DFS)
DFS was assessed in participants achieving complete response (CR) including complete response unconfirmed (Cru) and was defined as the period from the date of the initial CR/CRu until the date of relapse or death from any cause. CR: 1) disappearance of all evidence/symptoms of disease, 2) lymph nodes and nodal masses normal size, 3) enlarged spleen must have regressed in size, 4) normal bone marrow; CRu: see 1) and 3) of CR plus \> 75% decrease in residual lymph node mass, indeterminate bone marrow. Reported here is the truncated mean estimate based on Kaplan-Meier analysis.
Time frame: From time of first dose of rituximab IV before study enrollment up to end of study (up to approximately 62 months)
Treatment Response Rate
Treatment response rate was classified according to the International Working Group (IWG) response criteria: CR/Cru, partial response (PR), stable disease (SD) and PD. CR: 1) disappearance of all evidence/symptoms of disease, 2) lymph nodes and nodal masses normal size, 3) enlarged spleen must have regressed in size, 4) normal bone marrow; CRu: see 1) and 3) of CR plus \> 75% decrease in residual lymph node mass, indeterminate bone marrow; PR: \>/= 50% decrease lymph nodes and nodal mass size; decrease in liver/spleen size, no new sites; SD: less than a PR, but is not PD; PD: \>/= 50% increase lymph nodes and nodal mass size, any new lesion, enlarged liver/spleen, reappearance bone marrow abnormalities.
Time frame: 4-6 weeks after the last dose of Induction (Up to approximately 8 months)
| Milestone | Subcutaneous Rituximab |
|---|---|
| Started | 140 |
| Completed | 106 |
| Not completed | 34 |
| Withdrew: Other | 9 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: Other reason | 2 |
| Withdrew: Lost to follow-up | 15 |
| Withdrew: Investigator decision | 2 |
| Withdrew: Death | 4 |
AARs were defined as all adverse events (AEs) occurring within 24 hours of rituximab SC administration and which were considered related to study drug. AARs included infusion/injection-related reactions (IIRRs), injection-site reactions, administration site conditions and all symptoms thereof. Grading was completed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.0.
| percentage of participants | Diffuse Large B-Cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Subcutaneous Rituximab |
|---|---|---|---|
| At Least One AAR | 34.5 | 52.3 | 48.6 |
| At Least One AAR Grade ≥ 3 | 0 | 2.7 | 2.1 |
| At Least One Serious AARs | 0 | 1.8 | 1.4 |
| Generalised or Remote from the Injection Site AARs | 57.9 | 11.1 | 15.1 |
| Localised at the injection site AARs | 42.1 | 88.9 | 84.9 |
An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsen during a study are also considered as adverse events. Grading was completed according to the CTCAE, version 4.0.
| percentage of participants | Diffuse Large B-Cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Subcutaneous Rituximab |
|---|---|---|---|
| Percentage of Participants With At Least One Grade >/= 3 Adverse Events (AEs) | 48.3 | 36.0 | 38.6 |
Grading of IIRRs was completed according to the CTCAE, version 4.0.
| percentage of participants | Diffuse Large B-Cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Subcutaneous Rituximab |
|---|---|---|---|
| Percentage of Participants With At Least One Grade >/= 3 Infusion/ Injection Related Reactions (IIRRs) | 0.0 | 2.7 | 2.1 |
SAE was defined as any experience that suggested a significant hazard, contraindication, side effect, or precaution, and fulfilled any of the following criteria: fatal (resulted in death), life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/ birth defect, was medically significant or required intervention to prevent any of the other outcomes listed here.
| percentage of participants | Diffuse Large B-Cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Subcutaneous Rituximab |
|---|---|---|---|
| Percentage of Participants With At Least One Serious Adverse Event (SAE) | 37.9 | 27.9 | 30.0 |
EFS was defined as the time from first dose of rituximab IV to first occurrence of progressive disease (PD) or relapse, according to the International Working Group (IWG) response criteria or initiation of a non-protocol-specified anti-lymphoma therapy or death, whichever occurs first. PD: \>/= 50% increase lymph nodes and nodal mass size, any new lesion, enlarged liver/spleen, reappearance bone marrow abnormalities.
| months | Diffuse Large B-Cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Subcutaneous Rituximab |
|---|---|---|---|
| Event-Free Survival (EFS) | 25.79 (20.800 to 30.776) | 54.39 (51.416 to 57.362) | 52.314 (49.162 to 55.466) |
PFS was defined as the time from first dose of rituximab IV to the first occurrence of progressive disease (PD) or relapse, according to the International Working Group (IWG) response criteria or death from any cause. PD: \>/= 50% increase lymph nodes and nodal mass size, any new lesion, enlarged liver/spleen, reappearance bone marrow abnormalities.
| months | Diffuse Large B-Cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Subcutaneous Rituximab |
|---|---|---|---|
| Progression-Free Survival (PFS) | 27.952 (23.443 to 32.460) | 54.389 (51.416 to 57.362) | 53.118 (50.108 to 56.127) |
OS was defined as the time from first dose of rituximab IV to death from any cause.
| months | Diffuse Large B-Cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Subcutaneous Rituximab |
|---|---|---|---|
| Overall Survival (OS) | 37.42 (33.354 to 41.485) | 60.61 (59.692 to 61.535) | 59.516 (57.999 to 61.033) |
DFS was assessed in participants achieving complete response (CR) including complete response unconfirmed (Cru) and was defined as the period from the date of the initial CR/CRu until the date of relapse or death from any cause. CR: 1) disappearance of all evidence/symptoms of disease, 2) lymph nodes and nodal masses normal size, 3) enlarged spleen must have regressed in size, 4) normal bone marrow; CRu: see 1) and 3) of CR plus \> 75% decrease in residual lymph node mass, indeterminate bone marrow. Reported here is the truncated mean estimate based on Kaplan-Meier analysis.
| months | Diffuse Large B-Cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Subcutaneous Rituximab |
|---|---|---|---|
| Disease-Free Survival (DFS) | 26.062 (23.510 to 28.613) | NA (NA to NA) | 33.044 (31.489 to 34.600) |
Treatment response rate was classified according to the International Working Group (IWG) response criteria: CR/Cru, partial response (PR), stable disease (SD) and PD. CR: 1) disappearance of all evidence/symptoms of disease, 2) lymph nodes and nodal masses normal size, 3) enlarged spleen must have regressed in size, 4) normal bone marrow; CRu: see 1) and 3) of CR plus \> 75% decrease in residual lymph node mass, indeterminate bone marrow; PR: \>/= 50% decrease lymph nodes and nodal mass size; decrease in liver/spleen size, no new sites; SD: less than a PR, but is not PD; PD: \>/= 50% increase lymph nodes and nodal mass size, any new lesion, enlarged liver/spleen, reappearance bone marrow abnormalities.
| percentage of participants | Diffuse Large B-Cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Subcutaneous Rituximab |
|---|---|---|---|
| Complete Response (CR) | 62.1 | 66.7 | 64.3 |
| Complete Response Unconfirmed (CRU) | 3.4 | 7.4 | 5.4 |
| Partial Response (PR) | 3.4 | 11.1 | 7.1 |
| Stable Disease (SD) | 0.0 | 3.7 | 1.8 |
| Progressive disease (PD) | 17.2 | 7.4 | 12.5 |
| Unable to Assess (UA) | 6.9 | 0.0 | 3.6 |
| Not Evaluable | 6.9 | 3.7 | 5.4 |
Collected over From start of recruitment (10 months period) up to end of treatment at 32 months (total period up to 42 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Subcutaneous Rituximab | 4/140 (2.9%) | 42/140 (30%) | 117/140 (83.6%) |
| Event | Subcutaneous Rituximab |
|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 12/140 |
| NeutropeniaBlood and lymphatic system disorders | 10/140 |
| PneumoniaInfections and infestations | 4/140 |
| Respiratory tract infectionInfections and infestations | 4/140 |
| GastroenteritisInfections and infestations | 3/140 |
| Abdominal painGastrointestinal disorders | 2/140 |
| Pneumonia pneumococcalInfections and infestations | 2/140 |
| UrosepsisInfections and infestations | 2/140 |
| AgranulocytosisBlood and lymphatic system disorders | 1/140 |
| Atrial fibrillationCardiac disorders | 1/140 |
| Event | Subcutaneous Rituximab |
|---|---|
| ErythemaSkin and subcutaneous tissue disorders | 36/140 |
| AstheniaGeneral disorders | 31/140 |
| NeutropeniaBlood and lymphatic system disorders | 24/140 |
| Respiratory tract infectionInfections and infestations | 23/140 |
| DiarrhoeaGastrointestinal disorders | 22/140 |
| Viral upper respiratory tract infectionInfections and infestations | 21/140 |
| Back painMusculoskeletal and connective tissue disorders | 15/140 |
| PyrexiaGeneral disorders | 14/140 |
| ParaesthesiaNervous system disorders | 14/140 |
| CoughRespiratory, thoracic and mediastinal disorders | 14/140 |
Intent-to-Treat (ITT) population included all enrolled participants. All analyses described have been performed by type of lymphoma (DLBCL/ FL) and overall.
| Age, Continuous(years) | Diffuse Large B-Cell Lymphoma | Follicular Lymphoma | Total |
|---|---|---|---|
| Mean | 62.5 ± 12.0 | 59.6 ± 12.5 | 60.2 ± 12.4 |
| Sex: Female, Male(Participants) | Diffuse Large B-Cell Lymphoma | Follicular Lymphoma | Total |
|---|---|---|---|
| Female | 17 | 58 | 75 |
| Male | 12 | 53 | 65 |
| Race/Ethnicity, Customized(Participants) | Diffuse Large B-Cell Lymphoma | Follicular Lymphoma | Total |
|---|---|---|---|
| Black | 0 | 1 | 1 |
| Caucasian | 29 | 110 | 139 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2013 to primary completion in Apr 2017, 41 months.
Results were first posted in Jul 2018, 1 year 2 months after primary completion.
Of 41 industry-sponsored phase 3 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 84. This study's 41 months is below that.
Counting every sponsor, half of 58 studies reached it within 68 months; a quarter within 43 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rituximab